^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia
Published date:
11/04/2021
Excerpt:
CONTRADICTING EVIDENCE:...this multicenter, open-label, phase 1b trial (NCT03625505) to evaluate Ven + Gilt for R/R AML. Here, we report final response and survival endpoints, and molecular clearance among patients (pts) treated at the recommended phase two dose (RP2D)....Pts in the dose expansion cohort received Ven 400 mg + Gilt 120 mg (RP2D) daily in 28-day cycles, following Ven ramp-up....mCRc for DNMT3A+ and DMNT3Awt pts were 82.4% and 64.3%, respectively.
DOI:
10.1182/blood-2021-150743
Trial ID:
Source:
Title:
1945 Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Published date:
11/04/2020
Excerpt:
In 10 pts who were refractory to or relapsed after ‘triplet’ therapy, the most frequent mutations at screening were DNMT3A (4), IDH1/2 (4), and N/KRAS (3).
Secondary therapy:
decitabine
